Dipartimento di Medicina Veterinaria, Università degli Studi di Bari, 70010, Valenzano, Italy.
Arcoblu s.r.l., Via Alessandro Milesi 5, 20133, Milano, Italy.
Parasit Vectors. 2019 Jan 11;12(1):25. doi: 10.1186/s13071-018-3262-1.
The present study evaluated the therapeutic effectiveness of moxidectin 1.0% (w/v) and imidacloprid 10% (w/v) (Advocate® spot-on solution for cats, Bayer Animal Health) against natural infections with the eyeworm Thelazia callipaeda in cats. This study was conducted as a GCP, negative-controlled, blinded and randomised field study in privately owned cats living in an area in southern Italy where T. callipaeda is enzootic.
The study was carried out in 30 cats (19 females and 11 males, aged from 8 months to 5 years, weighing 1.2-5.2 kg) of different breeds, naturally infected by T. callipaeda. At study inclusion (Day 0), animals were physically examined and the infection level was assessed by examination of both eyes for clinical score and live adult T. callipaeda count. Each cat was weighed and randomly assigned to one of the treatment groups (G1: Advocate, G2: untreated control). Clinical assessments and T. callipaeda adult counts were performed on Day 14. At the study completion visit on Day 28, clinical assessments and counts of T. callipaeda adults and larvae were performed. All cats were daily observed by their owners and general health conditions were recorded during the entire period of the study.
The primary effectiveness variable was the percentage of animals in G1 group (Advocate) showing a complete elimination (parasitological cure) of adult eye worms at Day 14 and Day 28 . The effectiveness of the treatment in the G1 group was 93.3 and 100% at Day 14 and Day 28 , respectively, when compared to group G2. Total worm count reduction from both eyes for Advocate was 96.3% on Day 14 and 100% on Day 28. Clinical data were confirmed by the examination of conjunctival pouch flushing. An overall reduction in the number of cats with lacrimation and conjunctivitis was observed following treatment despite the fact that in a few cats treated with Advocate clinical signs persisted due to the chronic nature of the disease.
Based on the results of the present trial, a single dose of Advocate was found to be safe and highly effective in the treatment of natural T. callipaeda infection in cats.
本研究评估了莫昔克丁 1.0%（w/v）和吡虫啉 10%（w/v）（拜耳动物保健公司的 Advantix® 猫用滴剂）对意大利南部一个天然感染眼线虫 Thelazia callipaeda 的猫的治疗效果。本研究是在一个 GCP、阴性对照、盲法和随机的现场研究中进行的，涉及的猫是在眼线虫流行的地区，由私人拥有的猫。
这项研究是在 30 只猫（19 只雌性和 11 只雄性，年龄从 8 个月到 5 岁，体重 1.2-5.2 公斤）中进行的，这些猫都被天然感染了眼线虫。在研究开始时（第 0 天），对动物进行了身体检查，并通过检查两只眼睛的临床评分和活成虫眼线虫的数量来评估感染程度。每只猫都称重，并随机分配到治疗组之一（G1：Advantix，G2：未治疗对照组）。在第 14 天进行临床评估和眼线虫成虫计数。在第 28 天的研究完成访视时，进行临床评估和眼线虫成虫和幼虫计数。所有猫都由其主人每天观察，并在整个研究期间记录一般健康状况。
主要的有效性变量是 G1 组（Advantix）中动物在第 14 天和第 28 天完全消除（寄生虫学治愈）成虫眼线虫的百分比。第 14 天和第 28 天，G1 组的治疗效果分别为 93.3%和 100%，而 G2 组为 100%。第 14 天和第 28 天，Advantix 对双眼的总虫数减少了 96.3%和 100%。临床数据得到结膜囊冲洗检查的证实。尽管在一些接受 Advantix 治疗的猫中，由于疾病的慢性性质，临床症状仍然存在，但治疗后观察到流泪和结膜炎的猫数量总体减少。
根据本试验的结果，单次使用 Advantix 被发现对猫的天然眼线虫感染是安全且非常有效的。
